search
Back to results

Individualized Telemedical Assistance for Lifestyle Modification in the Treatment of Obesity and Cardiometabolic Risk Prevention (PREDIRCAM 2)

Primary Purpose

Obesity Type I and II

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Telemedic assistance with a technological system
Standard care
Sponsored by
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity Type I and II

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Preclinical Phase:

1. People over 18 years with or without obesity and with ability for technology management

Clinical Phase:

  1. People between 18 and 65 years.
  2. Obesity defined as a body mass index (BMI) greater than or equal to 30 kg/m2:

    1. Grade I or II without sleep apnea syndrome and ischemic heart disease
    2. Absence of metabolic processes (dyslipidemia) or associated hypertension requiring drug treatment at the time of inclusion in the study.
  3. People with ability for technology management

Exclusion Criteria:

Preclinical Phase:

1. Serious illness and / or disabling

Clinical Phase:

  1. Diabetes defining according to American Diabetes Association (ADA) criteria.
  2. Subjects with moderate to severe active disease at the time of inclusion in the study protocol
  3. Impaired glucose metabolism related diseases associated with diabetes mellitus or drugs interfering carbohydrate metabolism.
  4. Cardiovascular disease
  5. Dyslipidemia or hypertension requiring drug treatment.
  6. Alcohol consumption
  7. Pregnancy
  8. Serious illness and / or disabling

Sites / Locations

  • Hospital de la Santa Creu i Sant Pau

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Conventional assistance

Telemedic assistance

Arm Description

Usual treatment of obesity in terms of monitoring lifestyle habits

telemedical assistance with a technological system to provide a continuous monitoring of lifestyle habits and individualized treatment of obesity

Outcomes

Primary Outcome Measures

Weight loss

Secondary Outcome Measures

Cardiometabolic risk prevention
We will measure different parameters related to cardiovascular risk, such as adiponectine, tumour necrosis factor, Homeostasis Model Assessment, etc.at the beginning and at the end of the study

Full Information

First Posted
August 7, 2013
Last Updated
March 6, 2018
Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborators
Grupo de Bioingenieria y Telemedicina -ETSI Telecomunicacion. Universidad Politecnica de Madrid, Spanish Clinical Research Network - SCReN
search

1. Study Identification

Unique Protocol Identification Number
NCT01919372
Brief Title
Individualized Telemedical Assistance for Lifestyle Modification in the Treatment of Obesity and Cardiometabolic Risk Prevention
Acronym
PREDIRCAM 2
Official Title
Intensificación y monitorización telemática Personalizada de la modificación Del Estilo de Vida en el Tratamiento de la Obesidad y la prevención Del Riesgo cardiometabólico
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
October 29, 2015 (Actual)
Primary Completion Date
December 30, 2017 (Actual)
Study Completion Date
January 25, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborators
Grupo de Bioingenieria y Telemedicina -ETSI Telecomunicacion. Universidad Politecnica de Madrid, Spanish Clinical Research Network - SCReN

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This project is based on the contribution that could offer a technological system for a continuous monitoring, individualized treatment of obesity and prevention of cardiometabolic complications in high risk population. The main objective of PREDIRCAM study is to evaluate the benefits obtained with the use in high cardiometabolic risk individuals of a telemedical platform integrating applications for monitoring and providing recommendations to improve lifestyle habits (diet and physical activity) in a healthier way. The study population are obese subjects (type I or II) aged between 25 and 65 years with a 12 month follow-up. In this population it will be analysed the cost-effectiveness of a telemedic assistance with a technological system and its ability to modify lifestyle habits, reduce weight and cardiovascular risk associated parameters. Previously to the clinical implementation, a pilot study for testing the telemedical system will be made. Efficacy and security variables will be evaluated along the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity Type I and II

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
183 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Conventional assistance
Arm Type
Active Comparator
Arm Description
Usual treatment of obesity in terms of monitoring lifestyle habits
Arm Title
Telemedic assistance
Arm Type
Experimental
Arm Description
telemedical assistance with a technological system to provide a continuous monitoring of lifestyle habits and individualized treatment of obesity
Intervention Type
Device
Intervention Name(s)
Telemedic assistance with a technological system
Other Intervention Name(s)
PREDIRCAM
Intervention Type
Other
Intervention Name(s)
Standard care
Primary Outcome Measure Information:
Title
Weight loss
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Cardiometabolic risk prevention
Description
We will measure different parameters related to cardiovascular risk, such as adiponectine, tumour necrosis factor, Homeostasis Model Assessment, etc.at the beginning and at the end of the study
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Preclinical Phase: 1. People over 18 years with or without obesity and with ability for technology management Clinical Phase: People between 18 and 65 years. Obesity defined as a body mass index (BMI) greater than or equal to 30 kg/m2: Grade I or II without sleep apnea syndrome and ischemic heart disease Absence of metabolic processes (dyslipidemia) or associated hypertension requiring drug treatment at the time of inclusion in the study. People with ability for technology management Exclusion Criteria: Preclinical Phase: 1. Serious illness and / or disabling Clinical Phase: Diabetes defining according to American Diabetes Association (ADA) criteria. Subjects with moderate to severe active disease at the time of inclusion in the study protocol Impaired glucose metabolism related diseases associated with diabetes mellitus or drugs interfering carbohydrate metabolism. Cardiovascular disease Dyslipidemia or hypertension requiring drug treatment. Alcohol consumption Pregnancy Serious illness and / or disabling
Facility Information:
Facility Name
Hospital de la Santa Creu i Sant Pau
City
Barcelona
ZIP/Postal Code
08025
Country
Spain

12. IPD Sharing Statement

Learn more about this trial

Individualized Telemedical Assistance for Lifestyle Modification in the Treatment of Obesity and Cardiometabolic Risk Prevention

We'll reach out to this number within 24 hrs